Curasight A/S (NGM:CURAS)

Sweden flag Sweden · Delayed Price · Currency is SEK · Price in DKK
9.28
+1.38 (17.47%)
At close: Dec 4, 2025
-19.30%
Market Cap 658.09M
Revenue (ttm) n/a
Net Income (ttm) -71.43M
Shares Out 45.87M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 331,993
Average Volume 100,548
Open 8.18
Previous Close 7.90
Day's Range 8.18 - 9.54
52-Week Range 1.80 - 11.90
Beta 0.02
RSI 85.67
Earnings Date Nov 27, 2025

About Curasight

Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. It develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. The company is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2013
Employees 4
Stock Exchange Nordic Growth Market
Ticker Symbol CURAS
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements

News

There is no news available yet.